busulfan

(redirected from Busulfex)
Also found in: Medical, Encyclopedia.

bu·sul·fan

 (byo͞o-sŭl′fən)
n.
An alkylating agent, C6H14O6S2, that is used as an antineoplastic drug in the treatment of chronic myelogenous leukemia.

[bu(tane) + alteration of sulfon(ate).]

busulfan

(bjuːˈsʌlfæn)
n
a drug used to treat cancer
Translations

busulfan

n busulfán m, busulfano (INN)
References in periodicals archive ?
M2 EQUITYBITES-December 5, 2017-Mylan & Aspen partnership unveils generic Busulfex Injection
M2 PHARMA-December 5, 2017-Mylan & Aspen partnership unveils generic Busulfex Injection
In the hospital setting, ESP's IV Busulfex is marketed as a preconditioning chemotherapeutic agent in bone-marrow transplant, and is a natural fit in view of our right to potentially reacquire the rights to Zenapax in the transplant indication by 2007.
Kirin has strong presence in hematology field through its product pipeline including CliniMACS, Busulfex and second-generation of G-CSF in Japan.
General and administrative costs will decrease slightly following the sale of Busulfex and related staff changes.
Minnetonka, MN, worldwide rights to Busulfex Injection, an intravenous formulation of the alkylating agent busulfan, a drug often used in bone marrow transplantation.
IV BUSULFEX (busulfan) Injection is indicated for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation; this includes acute lymphocytic leukemia, acute non-lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, myelodysplastic syndrome and several genetic diseases.
This investment in oncology is also illustrated by major efforts in R&D partnerships, such as the licensing agreement with Orphan Medical for Busulfex in 1999, and research agreements signed last year with Celera Genomics and other biotechnology companies.
Four patients with different kinds of malignancies [high-grade non-Hodgkin lymphoma (n = 2), Hodgkin disease (n = 1), and plasmocytoma (n = 1)] were treated with Busulfex [TM] [6 g/L solution of busulfan dissolved in N,N-dimethylacetamide-polyethylene glycol (33:67 by volume); Orphan Medical] in conditioning regimes for HSCT.
Minneapolis, MN, has received approval from Canada's Therapeutic Products Programme (TPP) to market Busulfex Injection.
Minnetonka, MN, has received approval from the Food and Drug Administration (FDA) to market Busulfex (busulfan) Injection treatment to help prepare blood cancer patients for bone marrow transplants.